Literature DB >> 15073809

Prescription drug utilization following patient co-payment changes in Australia.

P McManus1, N Donnelly, D Henry, W Hall, J Primrose, J Lindner.   

Abstract

In November 1990 major patient co-payment changes were introduced into the Pharmaceutical Benefits Scheme (PBS), which accounts for around 90% of all community prescriptions in Australia. Interrupted time series analyses were performed to assess the impact of these co-payment changes on the prescription levels of defined groups of 'discretionary' and 'essential' drugs for both the general community and for a subgroup comprising elderly returned servicemen and women. While the co-payment changes themselves had a significant immediate effect on lowering the use of both categories of drugs, the effects were substantially larger for the 'discretionary' groups in both cases. Notably there was a clear post-intervention trend for increased prescriptions of 'essential' drugs after the initial decline, which was not evident for the 'discretionary' drugs. The introduction of programmes to compensate high risk groups in Australia may have enabled the co-payment to become a more selective policy instrument than has been shown in other settings.

Entities:  

Year:  1996        PMID: 15073809     DOI: 10.1002/(SICI)1099-1557(199611)5:6<385::AID-PDS246>3.0.CO;2-8

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

Review 1.  How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011.

Authors:  Astrid Kiil; Kurt Houlberg
Journal:  Eur J Health Econ       Date:  2013-08-29

2.  Prescription charges: change overdue? Britain can learn from systems of copayments based on drugs' effectiveness.

Authors:  T Walley
Journal:  BMJ       Date:  1998-08-22

3.  Prescription medicines: decision-making preferences of patients who receive different levels of public subsidy.

Authors:  Jane Robertson; Evan Doran; David A Henry; Glenn Salkeld
Journal:  Health Expect       Date:  2011-08-12       Impact factor: 3.377

4.  Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia.

Authors:  Karla L Seaman; Frank M Sanfilippo; Elizabeth E Roughead; Max K Bulsara; Anna Kemp-Casey; Caroline Bulsara; Gerald F Watts; David Preen
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

5.  The effect of a change in co-payment on prescription drug demand in a National Health System: The case of 15 drug families by price elasticity of demand.

Authors:  Cristina Hernández-Izquierdo; Beatriz González López-Valcárcel; Stephen Morris; Mariya Melnychuk; Ignacio Abásolo Alessón
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

Review 6.  The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis.

Authors:  Sarah-Jo Sinnott; Claire Buckley; David O'Riordan; Colin Bradley; Helen Whelton
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

7.  What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.

Authors:  Marin C Gemmill; Sarah Thomson; Elias Mossialos
Journal:  Int J Equity Health       Date:  2008-05-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.